Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness

Juhl, C. B.; Schmitz, O.; Pincus, S.; Holst, J. J.; Veldhuis, J.; Pørksen, N.
May 2000
Diabetologia;May2000, Vol. 43 Issue 5, p583
Academic Journal
Aims/hypothesis. The enteric incretin hormone, glucagon-like peptide-1 (GLP-1), is a potent insulin secretagogue in healthy humans and patients with Type II (non-insulin-dependent) diabetes mellitus. In this study we assessed the impact of short-term GLP-1 infusion on pulsatile insulin secretion in Type II diabetic patients. Methods. Type II diabetic patients (n = 8) were studied in a randomised cross-over design. Plasma insulin concentration time series were obtained during basal conditions and during infusion with saline or GLP-1 (1.2 pmol/l · kg–1· min–1) on 2 separate days. Plasma glucose was clamped at the initial concentration by a variable glucose infusion. Serum insulin concentration time series were evaluated by deconvolution analysis, autocorrelation analysis, spectral analysis and approximate entropy. Results. Serum insulin concentrations increased by approximately 100 % during GLP-1 infusion. Pulsatile insulin secretion was increased as measured by secretory burst mass (19.3 ± 3.8 vs 53.0 ± 10.7 pmol/l/pulse, p = 0.02) and secretory burst amplitude (7.7 ± 1.5 vs 21.1 ± 4.3 pmol/l/min, p = 0.02). A similar increase in basal insulin secretion was observed (3.6 ± 0.9 vs 10.2 ± 2.2 pmol/l/min, p = 0.004) with no changes in the fraction of insulin delivered in pulses (0.50 ± 0.06 vs 0.49 ± 0.02, p = 0.84). Regularity of secretion was unchanged as measured by spectral analysis (normalised spectral power: 5.9 ± 0.6 vs 6.3 ± 0.8, p = 0.86), autocorrelation analysis (autocorrelation coefficient: 0.19 ± 0.04 vs 0.18 ± 0.05, p = 0.66) and the approximate entropy statistic (1.48 ± 0.02 vs 1.51 ± 0.02, p = 0.86). Conclusion/interpretation. Short-term stimulation with GLP-1 jointly increases pulsatile and basal insulin secretion, maintaining but not improving system regularity in Type II diabetic patients. [Diabetologia (2000) 43: 583–588]


Related Articles

  • Linagliptin linked to better blood sugar in black patients with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Jun2012, Vol. 10 Issue 6, p17 

    The article focuses on the effectiveness of linagliptin in improving the blood sugar levels of African American patients with type 2 diabetes, as discussed by researcher James Thrasher at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress...

  • GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. Legakis, Ioannis // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2007, Vol. 1 Issue 3, p193 

    The gastrointestinal tract has a crucial role in the control of energy homeostasis through the action of multiple peptides known as incretins that act on distant target sites to promote the efficient uptake and storage of energy. In particular, GLP-1, an incretin hormone secreted from the...

  • Ileal Effect on Blood Glucose, HbA1c, and GLP-1 in Goto-Kakizaki Rats. Buchwald, Henry; Menchaca, Hector; Michalek, Van; Bertin, Nestor // Obesity Surgery;Nov2014, Vol. 24 Issue 11, p1954 

    Background: There have been enumerable studies on the effects of glucagon-like peptide-1 (GLP-1) on satiety and pancreatic islet function, stimulating the advocacy of surgical transposition of the ileum (rich in GLP-1-generating L-cells) higher in the gastrointestinal tract for earlier...

  • Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes. BOLLI, GEREMIA B.; LUCIDI, PAOLA; PORCELLATI, FRANCESCA; FANELLI, CARMINE G. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS220 

    The article examines the role of timely basal insulin replacement after metformin failure to sustain long-term blood glucose control in type 2 diabetes. Early and aggressive blood glucose-lowering intervention are used in addressing macrovascular complications. A discussion on the outcomes of...

  • Once-a-day GLP-1 controls glucose.  // GP: General Practitioner;6/12/2009, p7 

    The article reports on the findings of a recent study which revealed that glucagon-like peptide 1 (GLP-1) analogue liraglutide can improve blood glucose control when given once a day. It notes that said study was participated by nearly 500 patients with inadequately controlled type-2 diabetes...

  • A Single Dose of Vildagliptin (VILDA) Decelerates Gastric Emptying. (GE) in Patients with Type 2 Diabetes (T2DM). Woerle, Hans J.; Lindenberger, Thilo; Linke, Rainer; Foley, James E.; Ligueros-Saylan, Monica A.; Zhang, Yiming; He, Yan-Ling; Beglinger, Christoph; Goeke, Burkhard; Schirra, Joerg // Diabetes;Jun2007 Supplement 1, Vol. 56, pA133 

    The dipeptidyl peptidase IV (DPP-4) inhibitor, VILDA increases postprandial (pp) GLP-1 levels 2-4 fold; this is associated with improved islet function and lower glucose (GLU) excursions. Unlike GLP-1 analogs, a multiple dose study with VILDA utilizing 50 mg bid, did not shown the known GLP-I...

  • Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotheraphy. Fonseca, Vivian A.; Alvarado-Ruiz, Ricardo; Raccah, Denis; Boka, Gabor; Miossec, Patrick; Gerich, John E. // Diabetes Care;Jun2012, Vol. 35 Issue 6, p1225 

    OBJECTIVE - To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes. RESEARCH DESIGN AND METHODS - Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA1c 7-10%) allocated to one of four once-daily subcutaneous dose increase regimens:...

  • Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1. Mingming Gao; Hong Tian; Chen Ma; Xiangdong Gao; Wei Guo; Wenbing Yao // Applied Biochemistry & Biotechnology;Sep2010, Vol. 162 Issue 1, p155 

    Glucagon-like peptide-1 (GLP-1) is attracting increasing interest on account of its prominent benefits in type 2 diabetes. However, its clinical application is limited because of short biological half-life. This study was designed to produce a C-terminal site-specific PEGylated analog of...

  • Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Larsen, Jens; Damsbo, Peter; Hylleberg, Birgitte; Ng, Kevin; Larsen, J; Hylleberg, B; Ng, K; Damsbo, P // Diabetes Care;Aug2001, Vol. 24 Issue 8, p1416 

    Objective: To assess the efficacy and safety of glucagon-like peptide-1 (GLP-1) on the plasma glucose level when given as a continuous infusion for either 16 or 24 h per day to type 2 diabetic patients who were poorly controlled on sulfonylurea treatment.Research Design and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics